Spinosad, Milbemycin

Verify with FDA CVM →

3,647 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
3,647
Total Reports
68
Deaths Reported
190.0%
Death Rate

Active Ingredients

Spinosad, Milbemycin

Administration Routes

OralUnknownTopical

Species Affected

Dog 3,506
Unknown 127
Human 9
Cat 3
Other 2

Most Affected Breeds

Crossbred Canine/dog 720
Retriever - Labrador 248
Terrier - Yorkshire 171
Dog (unknown) 169
Unknown 138
Shih Tzu 136
Boxer (German Boxer) 136
Chihuahua 130
Dachshund (unspecified) 105
Poodle (unspecified) 98

Most Reported Reactions

Vomiting 2,279
Depression 635
Lack of efficacy (ectoparasite) - flea 253
Anorexia 236
Diarrhoea 207
Pruritus 173
UNPALATABLE 162
Accidental exposure 139
Trembling 122
Ataxia 108
Convulsion 105
Hypersalivation 72

Outcome Breakdown

Died
67 (62.0%)
Recovered/Normal
21 (19.4%)
Ongoing
8 (7.4%)
Outcome Unknown
8 (7.4%)
Recovered with Sequela
3 (2.8%)
Euthanized
1 (0.9%)

Data Summary

Metric Value
Total adverse event reports 3,647
Reports involving death 68
Case-fatality rate (reported events) 190.0%
Distinct species in reports 5
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Spinosad, Milbemycin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 3,647 adverse event reports referencing Spinosad, Milbemycin, including 68 reports in which the animal died — a 190.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Spinosad, Milbemycin. Reported administration routes include Oral, Unknown, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Spinosad, Milbemycin reports are Dog (3,506 reports), Unknown (127 reports), Human (9 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (720), Retriever - Labrador (248), Terrier - Yorkshire (171) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Spinosad, Milbemycin are Vomiting (2,279), Depression (635), Lack of efficacy (ectoparasite) - flea (253), Anorexia (236). Of the 108 reports with a coded outcome, Died is the leading category at 62.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Spinosad, Milbemycin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial